What will be the cost of COVID-19 vaccine?

News

BT NewsFlicks

Feedback

1/10

2/10

3/10

4/10

5/10

6/10

7/10

8/10

9/10

10/10

As per World Health Organization (WHO) ten candidates have reached the phase III trials for developing a vaccine. This means that the world is very close to receiving a cure for the COVID-19 pandemic. Here are the expected costs per two doses of vaccines being developed by candidates in phase III trials, as per data available with London based think tank Air Infinity.

Astra Zeneca's vaccine AZD1222 will most likely be the cheapest vaccine available to cure COVID-19, priced at close to $8 for two doses. The vaccine is expected to meet FDA (Food and Drug Administration) requirements by February 2021. As per Air Infinity, the manufacturer has received funding of more than $3 billion to develop the vaccine.

Russia's Gamaleya Research Institute is the maker of the vaccine Sputnik V. The vaccine has been named after the Soviet-era satellite launched into space in 1957. Sputnik V is expected to be the second most cheapest vaccine in the world for treating COVID-19. The vaccine is expected to meet FDA requirements by March 2021. The manufacturer has received funding of $ 40 million to make the vaccine.

Johnson & Johnson subsidiary, Janssen Research and development's vaccine Ad26COVS1 is expected to be priced at $20 for two doses. The vaccine is expected to meet FDA requirements by January 2021. To make the vaccine the manufacturer has received a funding support of $460 million.

Novavax is an American vaccine development company. It is developing a vaccine NVX-CoV2373 for curing COVID-19. The price of its vaccine is expected to be around $32 for two doses and the vaccine is expected to meet FDA requirements by June 2021.

Pfizer is also an American multinational company. It is one of the largest pharmaceutical companies in the world and its vaccine mRNA-BNT162 is currently in the phase III trial. The vaccine if successful will be priced at around $39 for two doses. The company is hopeful that its vaccine is expected to meet FDA requirements by the end of 2020. Pfizer has received $2.69 billion in funding to make a vaccine for COVID-19.

Sinovac is a China based vaccine maker which has a mission to eliminate human diseases. CoronaVac is the name of the vaccine that Sinovac is developing to cure COVID-19. Its vaccine is in the third phase trial of development. The vaccine is expected to meet FDA requirements by January 2021. The price of CoronaVac is expected to be around $60 for two doses.

Sinopharm is a Chinese pharmaceutical company based in Beijing. Its vaccine is estimated to meet FDA requirements by January 2021 and would cost around $7 for two doses. This vaccine is being developed in Wuhan which is also said to be the source of the COVID-19 pandemic.

Sinopharm is also developing another vaccine to cure COVID-19 in Beijing, the name of this vaccine is BBIBP-CorV. It is also stipulated to meet FDA requirements by January 2021 and it would be priced around $70 for two doses.

Moderna is an American biotechnology company based in Massachusetts. It is one of the frontrunners in the race for COVID-19 vaccine. Its vaccine mRNA-1273 is estimated to meet FDA requirements by the end of 2020. The company received $1.5 billion in funding. Its vaccine could also be the most expensive one going up to $74 for two doses.

Story: Mudit Kapoor

Design: Pragati Srivastava